HMGB1-mediated formation of IL-33–abundant NETs drives lung-to-kidney injury in severe pneumonia–associated acute kidney injury Authors: Mengqing Ma, Hao Zhang, Weijuan Deng, Xia Du, Mengxing Chen, Dawei Chen, Binbin Pan, Zhaowei Wang, Ting Chen, Caimei Chen, Xin Wan, Changchun Cao Published: 2026 ABSTRACT Acute kidney injury (AKI) is a common and fatal complication of severe pneumonia, yet the mechanisms linking pulmonary inflammation to remote kidney injury remain poorly understood. Multicenter cohort data (n = 300) revealed that the incidence of severe pneumonia–associated AKI (SP-AKI) was 53.6%, with a mortality rate of 24.2%. SP-AKI was associated with elevated circulating levels of HMGB1, NETs, and IL-33. Murine experiments demonstrated that alveolar HMGB1 triggers the formation of IL-33–enriched NETs, which migrate to the kidney and activate tubular ST2/NF-κB signaling, driving inflammation and apoptosis. Genetic knockout of IL-33, ST2, or the NET-forming key enzyme PAD4, as well as pharmacological inhibition of HMGB1, IL-33, or NETs, all attenuated lung and kidney injury. Exogenous HMGB1 amplified NET-mediated IL-33 release, establishing a self-sustaining HMGB1/NET/IL-33 feed-forward loop. PAD4 deficiency completely blocked NET generation and disrupted HMGB1/IL-33 signaling. This study identified and validated a damage-associated molecular pattern–driven (DAMP-driven) HMGB1/NET/IL-33 signaling axis that mediates remote kidney injury in SP-AKI, redefining NETs from local effectors to cross-organ pathogenic carriers, thereby providing potential DAMP-targeted therapeutic avenues for SP-AKI. Introduction Acute kidney injury (AKI) is a frequent and life-threatening complication in patients with severe pneumonia, substantially increasing short-term mortality and adversely affecting long-term outcomes (1, 2). Despite advances in antimicrobial therapy and organ support, the incidence of severe pneumonia–associated AKI (SP-AKI) remains unacceptably high, and effective disease-modifying treatments are still lacking. This sobering clinical reality highlights a fundamental unresolved question: How does lung injury transmit inflammatory signals to the kidney and drive remote organ damage? Traditionally, renal injury in severe pneumonia has been attributed primarily to systemic hemodynamic instability, hypoxia, and infection-related pathogen-associated molecular patterns (PAMPs) (3). However, accumulating clinical and experimental evidence indicates that damage-associated molecular patterns (DAMPs) play a central role in mediating remote organ injury (4). In this context, the lung-kidney axis has emerged as a critical determinant of outcomes in critically ill patients, yet the key molecular mediators that convey inflammatory signals from injured lungs to the kidney remain incompletely defined. In recent years, neutrophils and neutrophil extracellular traps (NETs) have been widely recognized as major amplifiers of tissue injury in acute inflammatory diseases (5, 6). Beyond their antimicrobial function, excessive NET formation contributes to endothelial dysfunction, microvascular damage, and epithelial toxicity, exerting pathogenic effects in both acute lung injury and AKI (7, 8). Nevertheless, most previous studies have focused on the local actions of NETs, and whether NETs generated in injured lungs can function as systemic mediators that propagate renal injury remains largely unexplored. Among the diverse repertoire of DAMPs, high-mobility group box 1 (HMGB1) has been identified as a key regulator of inflammation. HMGB1 is passively released during cell necrosis and orchestrates leukocyte recruitment, cytokine release, and NET formation. A substantial body of evidence demonstrates that HMGB1 drives NET generation through pattern recognition receptors such as TLR4, and that pharmacological inhibition of HMGB1 effectively attenuates inflammatory tissue damage (9). In parallel, the alarmin cytokine IL-33 has gained increasing attention for its role in acute lung injury, sepsis, and kidney disease (10–12). Notably, recent studies suggest that IL-33 can be processed and released in the context of NET formation, raising a compelling possibility: NETs may serve not only as inflammatory effector structures but also as carriers of bioactive cytokines (13). In the present study, we integrated a multicenter clinical cohort with multiomics analyses and complementary genetic and pharmacological approaches in murine models to systematically investigate lung-kidney inflammatory crosstalk in severe pneumonia. We identified and validated a DAMP-driven HMGB1/NET/IL-33 signaling axis and demonstrated its pivotal role in mediating remote renal injury in SP-AKI. Results Proteomics measurement and bioinformatics analysis conducted in patients with severe pneumonia. To identify molecular pathways associated with SP-AKI, we performed serum proteomic profiling in 10 patients with SP-AKI and 10 matched non-AKI controls. A total of 170 differentially expressed proteins were identified (122 upregulated, 48 downregulated) (Figure 1A). Notably, HMGB1 and HMGB2 ranked among the top 10 upregulated proteins, suggesting their potential involvement in SP-AKI pathogenesis (Figure 1B). Gene Ontology enrichment analysis revealed significant enrichment of immune-related biological processes, extracellular compartment localization, and binding-related molecular functions (Supplemental Figure 1A; supplemental material available online with this article; https://doi.org/10.1172/jci.insight.191979DS1). Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway analysis further highlighted activation of multiple inflammatory and injury-related pathways, including complement and coagulation cascades, mRNA surveillance, and ECM-receptor interactions (Supplemental Figure 1B). To identify key immune cell populations in disease progression, we analyzed single-cell RNA-seq (scRNA-seq) data from ex vivo–infected lung tissues of patients with COPD (14). Neutrophils emerged as the dominant immune population, with HMGB1 primarily expressed in alveolar epithelial cells (AT1 and AT2) and IL-33 highly enriched in neutrophils; NET-associated pathways were significantly activated (Figure 1, C and D). NET-associated pathways were significantly activated, and IL-33 was highly enriched in neutrophils (Figure 1, E and F). These findings were validated in independent scRNA-seq datasets from chemical-induced lung injury (GSE280922) (15) (Supplemental Figure 2, A–C) and COVID-19 pneumonia (GSE239835) (16) (Supplemental Figure 2, D–F), which consistently demonstrated enrichment of NET-related pathways and IL-33+ neutrophil accumulation (Supplemental Figure 2). Collectively, NET formation and neutrophil-derived IL-33 represent a conserved inflammatory signature across distinct lung injury etiologies. Elevated serum HMGB1, NET, and IL-33 levels are associated with SP-AKI in patients. A multicenter cohort of 300 patients with severe pneumonia from 3 hospitals was enrolled to validate bioinformatics findings (Supplemental Figure 3 and Supplemental Table 1). The overall incidence of AKI was 53.6%, with 10.3% of patients requiring continuous renal replacement therapy (CRRT) and an in-hospital mortality rate of 14.6%. Compared with non-AKI patients, those with AKI exhibited significantly higher mortality (24.2% vs 3.6%, P < 0.001) and CRRT utilization rates (19.3% vs. 0.0%, P < 0.001). Although AKI incidence was higher in blood culture–positive patients, most AKI cases occurred in culture-negative patients, and blood culture status was not an independent risk factor on multivariable analysis (Supplemental Tables 1 and 2). Serum HMGB1, NET components (citrullinated histone H3–DNA [CitH3-DNA], neutrophil elastase–DNA [NE-DNA], and myeloperoxidase-DNA [MPO-DNA] complexes), IL-33, and neutrophil gelatinase-associated lipocalin (NGAL) were significantly elevated in patients with AKI, increased progressively with AKI severity, and positively correlated with each other and with renal function indices (Figure 1, G–N). Flow cytometry confirmed elevated IL-33 expression in circulating neutrophils from patients with SP-AKI (Figure 1, O and P). To assess diagnostic performance, data from 1 center were divided into training and internal validation cohorts (70% and 30%, respectively), while patients from 2 additional hospitals constituted an external validation cohort (Supplemental Table 3). ROC analyses showed that NET markers and IL-33 consistently outperformed NGAL in discriminating SP-AKI. In the internal validation cohort, AUCs were 0.987 for IL-33, 0.958 for HMGB1, 0.914 for NE-DNA, 0.864 for MPO-DNA, and 0.822 for CitH3-DNA, versus 0.680 for NGAL. External validation yielded similar results, with NE-DNA achieving the highest AUC (0.974), followed by CitH3-DNA (0.948) and IL-33 (0.908) (Supplemental Figure 4 and Supplemental Tables 3 and 4). Optimal cutoff values derived from quartiles achieved clinically relevant sensitivity and specificity (Supplemental Table 4). Analysis of positive predictive value and negative predictive value across thresholds suggested that intermediate cutoffs were more suitable for identifying high-risk AKI patients, whereas lower or higher cutoffs favored AKI exclusion. HMGB1 upregulation induces neutrophil recruitment and NET formation in injured lungs. In patients with SP-AKI, serum HMGB1 levels positively correlated with NET markers, suggesting a potential role for HMGB1 in promoting NET formation (Figure 1N). To investigate the underlying mechanism, we established a murine SP-AKI model and focused on pulmonary HMGB1 dynamics. SP-AKI mice exhibited marked lung enlargement, pulmonary congestion, increased alveolar neutrophil infiltration, and thickened alveolar septa (Supplemental Figure 5, A–C). Lung RNA-seq analysis revealed significantly elevated HMGB1 expression accompanied by robust activation of innate immune responses, particularly pathways related to neutrophil chemotaxis, migration, and NET formation (Supplemental Figure 5, D–H). Consistently, HMGB1 expression was markedly upregulated in injured alveolar epithelial cells, as confirmed by immunofluorescence, Western blotting, and quantitative PCR (Figure 2, A, G, and R). This was accompanied by extensive neutrophil accumulation and pronounced NET deposition in lung tissues (Figure 2, A–K). Moreover, HMGB1 and NET components were significantly elevated in bronchoalveolar lavage fluid (BALF) and serum from SP-AKI mice (Figure 2, L–Q). Injured lungs also exhibited activation of NF-κB signaling and increased expression of proinflammatory cytokines, including IL-6, IL-1β, and TNF-α (Supplemental Figure 5, I–Q). NETs serve as systemic carriers of IL-33, preferentially driving renal injury. In injured lung tissues, quantitative PCR analysis revealed a marked upregulation of IL33 expression (Figure 2S). Consistently, immunofluorescence analysis demonstrated strong colocalization of IL-33 with NETs, marked by Ly6G and PAD4, indicating that IL-33 is incorporated into the NET scaffold rather than being passively released (Figure 2T). Given that NETs can disseminate systemically, we hypothesized that IL-33–bearing NETs act as carriers of remote organ injury. Multiplex tissue imaging revealed minimal NET deposition in the heart, liver, and spleen, whereas the kidney exhibited the most pronounced NET accumulation and associated tissue damage, identifying it as the primary target of systemic NET-mediated injury (Figure 3A). This renal vulnerability likely reflects its dense vascular network and high filtration capacity, which increase exposure to circulating inflammatory mediators. Consistent with this model, transcriptomic analysis of SP-AKI mouse kidneys showed robust activation of innate immune pathways (Supplemental Figure 6, A–D). scRNA-seq of renal autopsy tissues from patients with severe pneumonia (GSE210622) further revealed peritubular neutrophil accumulation in the kidneys (Figure 3, B–F) (17). Furthermore, NETs were readily detected in SP-AKI mouse kidneys, where IL-33 colocalized with NETs, implicating IL-33–enriched NETs in amplifying renal inflammation (Figure 3, G–J). IL-33–abundant NETs from the lungs serve as key mediators of kidney damage. To validate the role of IL-33–enriched NETs in lung-kidney crosstalk, we performed in vivo neutrophil depletion using an anti-Ly6G antibody before and after SP-AKI induction. Neutrophil depletion effectively eliminated circulating and tissue-resident neutrophils, reduced IL-33 levels, attenuated lung and kidney injury, and significantly improved survival (Figure 4, A–F), demonstrating that IL-33 within NETs is a critical mediator of renal damage. To further confirm that IL-33–enriched NETs originating from injured lungs drive kidney injury, we isolated neutrophils from lung tissues of WT or IL-33–knockout (IL-33–/–) SP-AKI mice and adoptively transferred them into neutrophil-depleted WT recipients. Transfer of WT SP-AKI neutrophils restored lung and kidney injury, whereas IL-33–/– neutrophils failed to do so. Moreover, transfer of WT SP-AKI neutrophils into otherwise-protected IL-33–/– recipients reestablished significant organ damage (Figure 4, G–N). Notably, previous studies have shown that neutrophils are short-lived innate immune cells, with a circulating half-life typically on the order of 6–8 hours (18). We found that neutrophils derived from injured lungs had a remarkably short half-life of less than 8 hours after adoptive transfer into the kidneys of recipient mice. In sharp contrast, neutrophils from healthy lungs remained detectable for over 24 hours after transfer. Despite their abbreviated survival, the injured lung–derived neutrophils exhibited significantly greater pathogenicity (Supplemental Figure 7). IL-33 drives renal tubular injury via ST2/NF-κB activation in vivo. To investigate how IL-33–bearing NETs trigger kidney injury upon reaching the kidneys, we performed RNA-seq analysis of renal tissues from SP-AKI mice, which revealed pronounced enrichment of NF-κB, TNF-α, and IL-1β signaling pathways (Supplemental Figure 6). Elevated expression of ST2 and NF-κB components (RelA, P50/P105) in renal tissues suggested that IL-33 binds ST2 on tubular cells, activating downstream NF-κB signaling and driving proinflammatory cytokine transcription (IL-6, TNF-α), thereby exacerbating renal inflammation (Figure 5). To further elucidate the bridging role of the IL-33/ST2 axis in NET-induced renal inflammation, we established SP-AKI models in IL-33–/– and ST2–/– mice and found that both NET formation and activation of the downstream NF-κB inflammatory pathway were significantly suppressed (Figure 6, A–O). These data further illustrated that NETs disseminate to the kidneys, where they activate the NF-κB pathway through the IL-33/ST2 axis, resulting in the release of proinflammatory factors that contribute to renal injury. Disruption of IL-33/ST2 signaling mitigated multiorgan damage in SP-AKI by abrogating NET-mediated inflammation. To determine whether this effect is mediated via the canonical IL-33/ST2 signaling axis, we adoptively transferred neutrophils from injured lung tissues isolated from WT or IL33–/– SP-AKI mice into ST2–/– recipients. Notably, ST2–/– mice were protected from renal injury regardless of whether the transferred neutrophils were IL-33–competent or –deficient, demonstrating that IL-33 must signal through ST2 to exert its pathological effects (Figure 6, P–T). Taken together, these results demonstrate that IL-33–enriched NETs formed in injured lung tissue disseminate to the kidneys and induce tubular epithelial cell damage via the IL-33/ST2/NF-κB signaling axis. HMGB1 amplifies renal inflammation by enhancing the NET/IL-33/ST2/NF-κB axis. To validate HMGB1’s role in promoting NETs and driving lung and kidney injury, we administered recombinant HMGB1 as an interventional challenge. Exogenous HMGB1 exacerbated kidney injury, increased IL-33 expression and NET formation in lung and kidney tissues, and activated ST2 and downstream NF-κB pathway markers in the kidneys. All effects were markedly reversed by glycyrrhizin, a functional HMGB1 inhibitor (Figure 7) (19), underscoring HMGB1’s pivotal role in driving the NET/IL-33/ST2/NF-κB axis. Notably, this regulatory circuit is not unidirectional. Previous studies have shown that IL-33 can, in turn, activate HMGB1 release and exacerbate inflammatory responses (20). Consistent with this, we observed significantly reduced levels of HMGB1 and NET formation in the serum, BALF, and tissues of IL-33–/– mice under injury conditions (Supplemental Figure 8). Importantly, therapeutic targeting of HMGB1, IL-33, or NETs initiated 6 hours after SP-AKI induction still significantly reduced NET levels in the circulation and BALF (Supplemental Figure 9, A–K), and concomitantly suppressed ST2/NF-κB activation in lung and kidney tissues, with efficacy comparable to preemptive intervention (Supplemental Figure 9, L and M). Collectively, these data reveal a self-amplifying feedback loop in SP-AKI whereby HMGB1 promotes IL-33–enriched NET formation, activates renal ST2/NF-κB signaling, and is further amplified by IL-33–driven HMGB1 release, identifying both HMGB1 and IL-33 as dual therapeutic targets. NET formation serves as a critical node in the HMGB1/IL-33 inflammatory loop. To determine whether NETs serve as a major source of IL-33, we analyzed scRNA-seq data from BALF of acute lung injury mice infected with Pseudomonas aeruginosa (PA) (GSE274823) (21). PA infection induced marked neutrophil recruitment, with IL-33 predominantly expressed by neutrophils. In PAD4/PAD2 double-knockout mice, although neutrophil infiltration persisted, NET formation was markedly reduced, and neutrophil IL-33 expression was nearly absent (Figure 8, A–D). Further analysis of immune cells from blood, lungs, and kidneys of WT sham, WT SP-AKI, IL-33–/– SP-AKI, and PAD4–/– SP-AKI mice confirmed injured neutrophils as the major source of IL-33 (Supplemental Figures 10–12). Importantly, PAD4 deficiency significantly reduced neutrophil-derived IL-33 release and alleviated kidney injury, indicating that neutrophil-derived IL-33 is dependent on NET formation (Figure 8, E–H). Moreover, PAD4 deficiency disrupted the HMGB1/NET/IL-33 inflammatory circuit and blunted the associated cytokine storm, as administration of exogenous recombinant HMGB1 failed to induce IL-33 overproduction. Notably, PAD4 deletion also abolished activation of the IL-33/ST2/NF-κB signaling pathway in the kidney (Figure 8, I–R). These findings establish NETs as both effector mediators and inflammatory amplifiers in SP-AKI lung-kidney crosstalk. Anti-HMGB1 and anti–IL-33 interventions attenuate NET formation and tubular injury in vitro. To further investigate the pathogenic roles of HMGB1 and IL-33 in NET-mediated tubular injury, we established an in vitro model mimicking the inflammatory microenvironment of SP-AKI. Serum from blood culture–negative patients with severe pneumonia was used to stimulate neutrophils from healthy donors in vitro. Flow cytometric analysis revealed a marked NET increase, characterized by coexpression of CD66b and MPO, especially in those who progressed to SP-AKI (Figure 9, A and B). Scanning electron microscopy showed typical NET morphology, including neutrophil membrane rupture and extensive extracellular chromatin fiber release (Figure 9F). Coculture of patient serum–induced NETs with HK-2 cells caused significant tubular cell apoptosis, which was markedly attenuated by glycyrrhizin, implicating HMGB1 as a key mediator (Figure 9, G–I). Immunofluorescence analysis confirmed IL-33 incorporation into NETs, colocalizing with MPO, identifying IL-33 as both a structural and functional NET component; anti–IL-33 neutralization significantly suppressed NET formation and HK-2 apoptosis (Figure 9, C–E, J, and K). Western blot and immunofluorescence analyses demonstrated that NET stimulation upregulated ST2 and activated NF-κB signaling in HK-2 cells, both of which were effectively reversed by anti–IL-33 treatment, reinforcing the pivotal role of IL-33/ST2/NF-κB signaling in NET-induced tubular injury (Figure 9, L–O). Consistent with this, pretreatment with NF-κB inhibitor Bay 11-7082 significantly alleviated NET-induced cytotoxicity, reducing NGAL levels and TNF-α secretion (Figure 9, P and Q). Together, these findings strongly support the conclusion that NETs contribute to renal tubular injury through the IL-33/ST2/NF-κB axis and highlight the therapeutic potential of targeting HMGB1 or IL-33 to mitigate NET-associated renal damage in SP-AKI. The proposed mechanism underlying SP-AKI is summarized in Figure 9R. Upon PAMP exposure, the lung mounts an immune response, releasing DAMPs such as HMGB1, NETs, and IL-33. HMGB1 promotes NET formation and IL-33 release, while IL-33 further damages epithelial cells, amplifying HMGB1 release — forming a self-sustaining HMGB1/NET/IL-33 loop. Notably, the release of IL-33 is dependent on HMGB1-induced NET activation. Circulating IL-33–enriched NETs drive systemic inflammation and, upon reaching the kidney, activate ST2/NF-κB signaling in tubular epithelial cells, causing inflammation and injury. Discussion SP-AKI is common and highly lethal, yet the mechanisms underlying lung-kidney inflammatory crosstalk remain incompletely defined. By integrating a multicenter clinical cohort with multiomics analyses and complementary genetic and pharmacological approaches in murine models, our study proposes and validates a DAMP-driven HMGB1/NET/IL-33 lung-kidney inflammatory axis, providing a mechanistic framework to explain the initiation and propagation of remote renal injury in the setting of severe pneumonia. In our multicenter cohort, we found that circulating levels of HMGB1, NET-related markers, and IL-33 were significantly associated with both the occurrence and severity of SP-AKI, and notably, these associations remained robust in patients with negative blood cultures. These findings suggest that the drivers of renal injury are not determined solely by PAMPs; rather, sterile inflammation and DAMPs may occupy a central role in the pathogenesis of SP-AKI. This concept is consistent with clinical observations that, in patients with severe pneumonia, antimicrobial therapy alone is often insufficient to control immune-mediated organ injury (22). In contrast, therapeutic strategies targeting key inflammatory mediators, such as cytokine-neutralizing approaches, may hold greater promise by interrupting inflammatory cascades in both local and remote organs, thereby improving overall clinical outcomes. In addition, we observed a consistent enrichment of NETs and IL-33+ neutrophils across multiple models of lung injury, indicating that this phenotype may represent a shared inflammatory hallmark of pulmonary damage. Given the established role of NETs in distant organ injury, we proposed that neutrophil-derived IL-33, released via NETs, could be a key mediator of renal damage secondary to lung injury. Previous studies have highlighted the pathogenic role of NETs in kidney injury, particularly in AKI (8, 23). The entry of circulating NETs into the kidney and their contribution to tubular damage likely involve multiple mechanisms, including their retention within the renal microvasculature (24), receptor-mediated uptake of NET-derived fragments by proximal tubular epithelial cells with ensuing inflammatory activation (25), chemokine-driven amplification of neutrophil recruitment and NET formation (26), and the direct cytotoxic effects of NETs following their translocation across the tubular barrier (27). This study primarily focuses on the direct damaging effects on renal tubular cells exerted by inflammatory mediators, specifically IL-33, released from NETs. Notably, although IL-33 can be expressed by multiple cell types, its sustained upregulation in neutrophils under injurious conditions was consistently observed across different experimental models. On this basis, we further focused on the mode of release and the biologically active form of neutrophil-derived IL-33 to elucidate its mechanistic role in kidney injury secondary to lung injury. As a prototypical alarmin cytokine, IL-33 binds to its receptor ST2L and activates NF-κB signaling, thereby promoting the production of proinflammatory cytokines and amplifying inflammatory responses (28). A key question, however, is how posttranslational modifications — particularly proteolytic processing and oxidative modification — shape the biological activity of IL-33. In the specific microenvironment of NET formation, in what form does IL-33 exist and exert its function? In the present study, IL-33 was predominantly released during NET formation, a process characterized by nuclear envelope disruption and a protease-rich milieu. Under such conditions, IL-33 is more likely to undergo proteolytic processing rather than oxidative inactivation. Consistent with this notion, previous studies have demonstrated that neutrophil-derived proteases, including NE, cathepsin G, and proteinase 3, cleave full-length IL-33 into shorter mature forms with enhanced biological activity (29). By contrast, although oxidative modification has been shown to rapidly inactivate extracellular IL-33 by disrupting its interaction with ST2 (30), this process is more likely to occur in oxygen-rich extracellular environments and may be less prominent in the protease-dense milieu associated with NET formation. Collectively, these lines of evidence suggest that the IL-33 detected in our study predominantly represents a protease-processed, biologically active form released during NET formation, rather than an oxidatively inactivated, functionally inert species. Moreover, our findings that renal ST2 signaling is responsive to IL-33 provide functional support for the notion that the IL-33 identified in this study is present largely in its bioactive form. In addition, our study further substantiates the critical role of the DAMP HMGB1 in driving NET formation and amplifying inflammatory responses. Our previous work demonstrated that, in patients with severe pneumonia requiring extracorporeal life support, mechanical ventilation–associated HMGB1 activation markedly promotes NET generation (31). These findings are consistent with multiple previous studies showing that HMGB1 induces NET formation, whereas its antagonists effectively suppress this process (9, 32, 33). Accordingly, targeting HMGB1 has been proposed as a potential therapeutic strategy to reduce the incidence and mortality of SP-AKI (34). Building on this framework, we further delineated a bidirectional regulatory relationship between HMGB1 and IL-33. We found that exogenous HMGB1 or its specific inhibitor respectively enhanced or suppressed IL-33 release, in line with previous reports describing an intrinsic IL-33 auto-amplification loop driven by HMGB1 (35–37). Importantly, we observed that genetic deletion of IL-33 not only reduced IL-33 levels but also significantly attenuated HMGB1 release and NET formation. These findings suggest that IL-33 functions not only as a structural component of NETs but also as a DAMP that feeds back to promote HMGB1 release from injured epithelial cells, thereby establishing a self-amplifying HMGB1/NET/IL-33 positive-feedback loop. Notably, under conditions of PAD4 deficiency, which specifically abrogates NET formation, exogenous HMGB1 stimulation failed to effectively induce IL-33 release. This result indicates that NET formation is a critical prerequisite for the establishment of the HMGB1/IL-33 inflammatory circuit. In this context, NETs do not merely act as downstream effector structures that amplify inflammation but rather serve as a central signaling bridge linking HMGB1 to IL-33. These genetic data further strengthen our proposed mechanistic model in which HMGB1 drives NET formation to facilitate the functional release of IL-33, while IL-33 in turn augments HMGB1-associated inflammatory responses, together forming a self-sustaining DAMP-driven inflammatory loop. This feedback circuit persistently fuels inflammatory responses and tissue injury during the development of SP-AKI, underscoring the central role of this signaling axis in disease pathogenesis. More importantly, in the present study, targeting HMGB1, IL-33, or NETs — in both preventive and therapeutic settings — consistently conferred significant protective effects, further supporting the translational potential of this pathway as a promising therapeutic target in SP-AKI. This study redefines NETs from mere local inflammatory effectors to cross-organ pathogenic carriers that link lung injury to remote kidney damage. Through integrated genetic and pharmacological evidence, we establish a causal role for the HMGB1/NET/IL-33 axis in SP-AKI, providing a mechanistically defined paradigm for interorgan inflammatory injury and laying a theoretical foundation for therapeutic strategies targeting DAMPs. We also recognize that lung-kidney interactions are orchestrated by a complex and multilayered regulatory network that extends beyond the HMGB1/NET/IL-33 axis examined here. In addition to humoral inflammatory mediators, accumulating evidence indicates that neuroimmune pathways play an important role in interorgan communication, including the regulation of inflammation and organ function by the autonomic nervous system (38, 39). However, the present study was specifically designed to delineate DAMP-driven humoral signaling mechanisms, and therefore did not address the potential contributions of neuroimmune circuits or other non-soluble regulatory pathways. Moreover, although our data support a pathogenic role for neutrophil-derived IL-33 in NET-mediated renal injury, future studies employing neutrophil-specific IL-33–deficient models will be required to definitively establish its causal contribution to the lung-kidney inflammatory axis. In summary, we showed that lung injury–derived HMGB1 drove the formation of IL-33–enriched NETs, which reached the kidney and exacerbated tubular inflammation through the IL-33/ST2/NF-κB axis, thereby promoting SP-AKI. These findings not only fill a critical mechanistic gap in our understanding of pneumonia-associated secondary kidney injury but also provide a translational framework for therapeutic strategies targeting the HMGB1/NET/IL-33 axis. Methods Further information can be found in Supplemental Methods. All oligonucleotide primers used in this study are provided in Supplemental Table 5, and all antibodies are listed in Supplemental Tables 6 and 7. Sex as a biological variable. For human studies, samples from both male and female participants were included (Supplemental Table 1), and no sex-specific differences were observed in the analyzed outcomes. In animal experiments, only male mice were used, as previous studies have reported that male mice develop more severe pneumonia following infection compared with female mice (40, 41). Study design and population. We conducted a prospective, multicenter cohort study at Sir Run Run Hospital of Nanjing Medical University, Nanjing First Hospital, and Wuxi People’s Hospital Affiliated with Nanjing Medical University. The study enrolled adult patients (≥18 years) diagnosed with severe pneumonia between January, 2022 and September, 2023. Exclusion criteria included (a) hospital stay less than 48 hours or incomplete clinical data; (b) less than 2 serum creatinine measurements during hospitalization; (c) end-stage renal disease requiring maintenance dialysis; and (d) AKI caused by nonpulmonary factors, previous nephrotoxic agent exposure, or contrast administration before admission. Construction of SP-AKI mouse model. Male C57BL/6 mice (8–10 weeks old, 20–25 g) were purchased from the Model Animal Research Center of Nanjing University, while IL-33–/– and ST2–/– mice were provided by Zhang Hongsong’s team (Nanjing First Hospital). PAD4–/– mice were purchased from Cyagen Biosciences Inc. Mice were anesthetized by inhalation of isoflurane, and 50 μL of PA suspension (1 × 108 CFU) was intratracheally inoculated to establish SP-AKI; sham received 50 μL sterile saline. Mice were euthanized at 24 hours after infection, and blood, BALF, lung, and kidney tissues were collected for analysis. Experimental cell sources and culture. HK-2 cells were obtained from Shanghai Zhongqiao Xinzhou Biotechnology Co., Ltd. Neutrophils were cultured in RPMI-1640 medium supplemented with 10% fetal bovine serum, while HK-2 cells were maintained in DMEM/F12 medium with 10% fetal bovine serum. All cells were incubated at 37°C in a humidified atmosphere containing 5% CO2. Intervention with anti–IL-33, anti-HMGB1, anti–NF-κB, and recombinant mouse HMGB1. In vitro, neutrophils were pretreated with anti–IL-33 neutralizing antibody (1 μg/mL; R&D Systems) for 4 hours; SP-AKI patient serum was incubated with glycyrrhizic acid (200 μM; MedChemExpress) for 24 hours; and HK-2 cells were pretreated with Bay 11-7082 (2 μM; Sigma-Aldrich) for 24 hours. In vivo, mice received intraperitoneal injections of recombinant HMGB1 (50 μg/kg; Sino Biological), glycyrrhizic acid (50 mg/kg; MedChemExpress), anti-HMGB1 antibody (100 μg/kg; Arigo), anti–IL-33 antibody (60 μg/kg; R&D Systems), or GSK484 (4 mg/kg; MedChemExpress); controls received equivalent volumes of sterile saline. Statistics. Normality was assessed using the Shapiro-Wilk test (<50 samples) or Kolmogorov-Smirnov test (≥50 samples). Normally distributed data are presented as mean ± SD and were analyzed by 2-tailed Student’s t test; non–normally distributed data are presented as median (IQR) and were analyzed using the Mann-Whitney U test. Multiple-group comparisons used 1-way or 2-way ANOVA with post hoc tests. Categorical variables were analyzed by χ2 test. Analyses were performed using SPSS 22.0 (IBM), GraphPad Prism 9.5.1, and R 4.2.2 (https://www.r-project.org/). Statistical significance was set at a P value of less than 0.05. Study approval. All animal experiments were approved by the Institutional Animal Care and Use Committee (protocol number: IACUC-2311001) and conducted in accordance with the institutional guidelines of Nanjing Medical University for animal experimentation. The human study was performed in accordance with the Declaration of Helsinki and approved by the Institutional Review Boards of Sir Run Run Hospital (2021-SR-042), Nanjing First Hospital (KY20230410-01-KS-01), and Wuxi People’s Hospital (KY22073), Nanjing Medical University. Written informed consent was obtained from all participants. Data availability. All the data generated or analyzed in our study are available as supplemental files. Bulk RNA-seq data generated in this study are deposited in the NCBI Gene Expression Omnibus (GEO) database under accession number GSE324794; proteomics data are available in the OMIX database under accession number OMIX015195. Values for all data points in graphs are reported in the Supporting Data Values file. Clinical data used in this study involve human participants and are not publicly available due to privacy and ethical restrictions. Author contributions C Cao and XW designed the study. MM and HZ conceived the study, interpreted data, and drafted the manuscript. WD, XD, MC, DC, BP, C Chen, TC, and ZW participated in the design of the study and acquired data. MM and HZ contributed equally to this work. The order of co–first authors was determined based on their relative contributions to the study. All authors revised the manuscript and approved the final version of the manuscript. Conflict of interest The authors have declared that no conflict of interest exists. Funding support National Natural Science Foundation of China (82170698 and 82500834). National Natural Science Foundation of China (82170698 and 82500834). Jiangsu Funding Program for Excellent Postdoctoral (2025ZB004). Jiangsu Funding Program for Excellent Postdoctoral (2025ZB004). The Major Project of Jiangsu Provincial Health Commission Medical Research (ZDB2020023). The Major Project of Jiangsu Provincial Health Commission Medical Research (ZDB2020023). The General Project of Jiangsu Provincial Health Commission Medical Research (H2023057). The General Project of Jiangsu Provincial Health Commission Medical Research (H2023057). Jiangsu Provincial Social Development Biomedical Research Fund (BE2023830). Jiangsu Provincial Social Development Biomedical Research Fund (BE2023830). Nanjing Municipal Health Science and Technology Development Special Fund Key Project (ZKX22035). Nanjing Municipal Health Science and Technology Development Special Fund Key Project (ZKX22035). Supplementary Material Supplemental data Unedited blot and gel images Supporting data values